ClinicalTrials.gg
Active, not recruitingNCT05433584SURPASS-EARLYUpdated Nov 12, 2026Results posted

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

A Phase 4 interventional study of Tirzepatide and Antihyperglycemic medication in Type 2 Diabetes, sponsored by Eli Lilly and Company. Active, not recruiting at 90 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Updated Nov 12, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
794
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
8th of 43
794 · median 160
Started
2022
with 3 others
Phase 4
10 of 43
4 open now
Primary completion
2025-10
later than 3 of 12 live
Registered
22nd of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 4 that started in 2022, is one of 10 in phase 4, reaches primary completion later than 3 of the 12 other live ones, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • T2D
  • Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have, within the last 4 years, been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
  • Have ≥7% to ≤9.5% as determined by the central laboratory.
  • Have been on a stable treatment of metformin only at least 90 days preceding baseline

    • with the minimum effective dose of ≥1500 mg/day, but not higher than the maximum approved dose per country-specific label, or
    • \<1500 mg/day in case of intolerance of full therapeutic dose.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have a history of chronic or acute pancreatitis any time prior to study entry
  • Have a history of

    • proliferative diabetic retinopathy
    • diabetic macular edema, or
    • no proliferative diabetic retinopathy requiring immediate or urgent treatment
  • Are at high risk for cardiovascular disease (CVD) in the investigator's opinion or have a history of any of these CV conditions prior to study entry

    • myocardial infarction
    • percutaneous coronary revascularization procedure
    • carotid stenting or surgical revascularization
    • nontraumatic amputation
    • peripheral vascular procedure (e.g., stenting or surgical revascularization)
    • cerebrovascular accident (stroke), or congestive heart failure
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over the counter, or alternative remedies
  • Have an estimated (eGFR) \<30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by chronic kidney disease-epidemiology equation as determined by central laboratory at screening.
  • Have been treated with any injectable glucagon-like peptide-1 (GLP-1) receptor agonists and insulin prior to screening.

    • Exception: use of insulin for gestational diabetes or short-term use (\<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
794 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants received tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 104 weeks. The starting dose of tirzepatide was 2.5 mg QW, which was increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5mg to 15 mg) until 15 mg or maximum tolerated dose (MTD) was reached.

    Drug: Tirzepatide

  • Active comparator
    Intensified Conventional Care (ICC)

    Participants received a glucose-lowering medication selected by the investigator, in accordance with local treatment guidelines and country-specific product labeling for 104 weeks.

    Drug: Antihyperglycemic medication

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugAntihyperglycemic medication

    As prescribed

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

Secondary outcomes

  1. Change From Baseline in HbA1c

    Time frame: Baseline, Week 208

  2. Change From Baseline in Weight

    Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  3. Change From Baseline in Weight

    Time frame: Baseline, Week 208

  4. Change From Baseline in Waist Circumference

    Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  5. Change From Baseline in Waist Circumference

    Time frame: Baseline, Week 208

  6. Change From Baseline in Fasting Serum Glucose (FSG)

    Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  7. Change From Baseline in Fasting Serum Glucose

    Time frame: Baseline, Week 208

  8. Percent Change From Baseline in Total Serum Cholesterol

    Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  9. Percent Change From Baseline in Total Serum Cholesterol

    Time frame: Baseline, Week 208

  10. Percent Change From Baseline in Serum Triglycerides

    Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  11. Percent Change From Baseline in Serum Triglycerides

    Time frame: Baseline, Week 208

  12. Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol

    Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  13. Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol

    Time frame: Baseline, Week 208

  14. Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol

    Values represented under Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  15. Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol

    Time frame: Baseline, Week 208

  16. Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol

    Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 104

  17. Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol

    Time frame: Baseline, Week 208

  18. Percentage of Participants Achieving HbA1c <7.0%

    Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Week 104

  19. Percentage of Participants Achieving HbA1c <7.0%

    Time frame: Week 208

  20. Percentage of Participants Achieving HbA1c ≤6.5%

    Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Week 104

  21. Percentage of Participants Achieving HbA1c ≤6.5%

    Time frame: Week 208

  22. Percentage of Participants Achieving HbA1c <5.7%

    Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Week 104

  23. Percentage of Participants Achieving HbA1c <5.7%

    Time frame: Week 208

  24. Percentage of Participants With >=5% Weight Loss From Baseline

    Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Baseline, Week 104

  25. Percentage of Participants With >=5% Weight Loss From Baseline

    Time frame: Baseline, Week 208

  26. Percentage of Participants With >=10% Weight Loss From Baseline

    Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Baseline, Week 104

  27. Percentage of Participants With >=10% Weight Loss From Baseline

    Time frame: Baseline, Week 208

  28. Percentage of Participants With >=15% Weight Loss From Baseline

    Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Baseline, Week 104

  29. Percentage of Participants With >=15% Weight Loss From Baseline

    Time frame: Baseline, Week 208

  30. Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)

    A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Percentage of participants was calculated by dividing the number of participants reaching target HbA1c, weight loss, no Hypoglycemia by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

    Time frame: Week 104

  31. Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)

    Time frame: Week 208

  32. Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)

    β-cell Glucose Sensitivity assessed by Oral Glucose Tolerance Test (OGTT). LS mean was determined using ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

    Time frame: Baseline, Week 104

  33. Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)

    Time frame: Baseline, Week 208

  34. Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)

    LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment. Insulin secretion rate adjusted for basal potentiation was defined as the ISR at a fixed glucose concentration of 9.2 mmol/L, adjusted for time-dependent potentiation of insulin secretion, and is expressed in pmol/min/m².

    Time frame: Baseline, Week 104

  35. Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration

    Time frame: Baseline, Week 208

  36. Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS)

    LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

    Time frame: Baseline, Week 104

  37. Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS)

    Time frame: Baseline, Week 208

  38. Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total Area Under the Curve [AUC0-180])

    LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

    Time frame: Baseline, Week 104

  39. Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total AUC[0-180])

    Time frame: Baseline, Week 208

  40. Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])

    LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

    Time frame: Baseline, Week 104

  41. Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])

    Time frame: Baseline, Week 208

  42. Change From Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning Score

    The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: Physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial (13 items). Items in Physical Function describe physical impacts related to general and specific physical activities. All items in physical domain are rated on a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined by MMRM model for post-baseline measures: Variable=Baseline + Geographic Region+Baseline HbA1c Group + Age + Treatment\*Time. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline)=Unstructured.

    Time frame: Baseline, Week 104

  43. Change From Baseline in the IWQOL-Lite-CT - Physical Functioning Score

    Time frame: Baseline, Week 208

07

Results

Posted Nov 12, 2026

Participant flow

The current results reported are for the primary completion date (i.e., up to 104 weeks). Additional results (week 208) will be reported at the time of final results reporting.

Participant flow — Overall Study
MilestoneTirzepatideIntensified Conventional Care (ICC)
Started398396
Received at least one dose of study drug397395
Completed359350
Not completed3946
Withdrew: Adverse event20
Withdrew: Assigned treatment by mistake63
Withdrew: Death21
Withdrew: Lost to follow-up912
Withdrew: Non-compliance with study drug10
Withdrew: Physician decision01
Withdrew: Pregnancy12
Withdrew: Protocol deviation12
Withdrew: Withdrawal by subject1219
Withdrew: Other56

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1cTirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Hemoglobin A1c (HbA1c)-2.24 ± 0.053-1.45 ± 0.052
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.79 · 95% CI -0.94 to -0.64
SecondaryChange From Baseline in HbA1c
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Weight

Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in Weight
Kilogram (kg)TirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Weight-15.8 ± 0.518-6.48 ± 0.513
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -9.32 · 95% CI -10.75 to -7.89
SecondaryChange From Baseline in Weight
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Waist Circumference

Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference
centimeter (cm)TirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Waist Circumference-13.30 ± 0.467-6.08 ± 0.463
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -7.22 · 95% CI -8.51 to -5.93
SecondaryChange From Baseline in Waist Circumference
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram per deciliter (mg/dL)TirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Fasting Serum Glucose (FSG)-60.1 ± 1.455-42.7 ± 1.438
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -17.4 · 95% CI -21.4 to -13.40
SecondaryChange From Baseline in Fasting Serum Glucose
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Total Serum Cholesterol

Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Total Serum Cholesterol
Percent changeTirzepatideIntensified Conventional Care (ICC)
Percent Change From Baseline in Total Serum Cholesterol-2.60 ± 1.072-2.76 ± 1.073
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = 0.920 · Geometric ls mean difference (net): 0.16 · 95% CI -2.86 to 3.27
SecondaryPercent Change From Baseline in Total Serum Cholesterol
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Serum Triglycerides

Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Serum Triglycerides
Percent changeTirzepatideIntensified Conventional Care (ICC)
Percent Change From Baseline in Serum Triglycerides-29.9 ± 1.577-13.61 ± 1.949
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -18.9 · 95% CI -23.84 to -13.61
SecondaryPercent Change From Baseline in Serum Triglycerides
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol

Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol
Percent changeTirzepatideIntensified Conventional Care (ICC)
Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol0.55 ± 1.919-3.19 ± 1.853
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = 0.162 · Geometric ls mean difference (net): 3.85 · 95% CI -1.51 to 9.52
SecondaryPercent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol

Values represented under Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol
Percent changeTirzepatideIntensified Conventional Care (ICC)
Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol-29.0 ± 1.579-12.84 ± 1.945
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -18.6 · 95% CI -23.5 to -13.38
SecondaryPercent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol

Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol
Percent changeTirzepatideIntensified Conventional Care (ICC)
Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol13.13 ± 1.0485.01 ± 0.973
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): 7.74 · 95% CI 5.00 to 10.55
SecondaryPercent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving HbA1c <7.0%

Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c <7.0%
percentage of participantsTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants Achieving HbA1c <7.0%95.0677.94
SecondaryPercentage of Participants Achieving HbA1c <7.0%
Time frame:
Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving HbA1c ≤6.5%

Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c ≤6.5%
percentage of participantsTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants Achieving HbA1c ≤6.5%91.065.50
SecondaryPercentage of Participants Achieving HbA1c ≤6.5%
Time frame:
Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving HbA1c <5.7%

Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Week 104
Reported as:
Number · percentage of participant
Percentage of Participants Achieving HbA1c <5.7%
percentage of participantTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants Achieving HbA1c <5.7%68.8426.65
SecondaryPercentage of Participants Achieving HbA1c <5.7%
Time frame:
Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants With >=5% Weight Loss From Baseline

Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Baseline, Week 104
Reported as:
Number · percentage of participants
Percentage of Participants With >=5% Weight Loss From Baseline
percentage of participantsTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants With >=5% Weight Loss From Baseline84.9852.90
SecondaryPercentage of Participants With >=5% Weight Loss From Baseline
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants With >=10% Weight Loss From Baseline

Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Baseline, Week 104
Reported as:
Number · percentage of participants
Percentage of Participants With >=10% Weight Loss From Baseline
percentage of participantsTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants With >=10% Weight Loss From Baseline67.6228.06
SecondaryPercentage of Participants With >=10% Weight Loss From Baseline
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants With >=15% Weight Loss From Baseline

Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Baseline, Week 104
Reported as:
Number · percentage of participants
Percentage of Participants With >=15% Weight Loss From Baseline
percentage of participantsTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants With >=15% Weight Loss From Baseline49.2312.80
SecondaryPercentage of Participants With >=15% Weight Loss From Baseline
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)

A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Percentage of participants was calculated by dividing the number of participants reaching target HbA1c, weight loss, no Hypoglycemia by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.

Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)
percentage of participantsTirzepatideIntensified Conventional Care (ICC)
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)61.8022.69
SecondaryPercentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)
Time frame:
Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)

β-cell Glucose Sensitivity assessed by Oral Glucose Tolerance Test (OGTT). LS mean was determined using ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · pmol/min/m^2/mM
Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)
pmol/min/m^2/mMTirzepatideIntensified Conventional Care (ICC)
Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)55.10 ± 2.73836.00 ± 2.725
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · ANCOVA · p = <.001 · Ls mean difference (net): 19.10 · 95% CI 11.51 to 26.69
SecondaryChange From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)

LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment. Insulin secretion rate adjusted for basal potentiation was defined as the ISR at a fixed glucose concentration of 9.2 mmol/L, adjusted for time-dependent potentiation of insulin secretion, and is expressed in pmol/min/m².

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · pmol/min/m^2
Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)
pmol/min/m^2TirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)168.72 ± 13.130131.24 ± 13.069
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · ANCOVA · p = 0.044 · Ls mean difference (net): 37.48 · 95% CI 1.09 to 73.86
SecondaryChange From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Oral Glucose Insulin Sensitivity (OGIS)

LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · mL/min/m^2
Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS)
mL/min/m^2TirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS)95.95 ± 5.10958.98 ± 5.092
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · ANCOVA · p = <.001 · Ls mean difference (net): 36.96 · 95% CI 22.80 to 51.13
SecondaryChange From Baseline in Oral Glucose Insulin Sensitivity (OGIS)
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total Area Under the Curve [AUC0-180])

LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · min*mmol/L
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total Area Under the Curve [AUC0-180])
min*mmol/LTirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total Area Under the Curve [AUC0-180])-1260.39 ± 28.841-897.05 ± 28.930
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · ANCOVA · p = <.001 · Ls mean difference (net): -363.34 · 95% CI -443.57 to -283.11
SecondaryChange From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total AUC[0-180])
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])

LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · min*mmol/L
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])
min*mmol/LTirzepatideIntensified Conventional Care (ICC)
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])-611.83 ± 21.623-387.12 ± 21.657
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · ANCOVA · p = <.001 · Ls mean difference (net): -224.71 · 95% CI -284.89 to -164.53
SecondaryChange From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

SecondaryChange From Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning Score

The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: Physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial (13 items). Items in Physical Function describe physical impacts related to general and specific physical activities. All items in physical domain are rated on a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined by MMRM model for post-baseline measures: Variable=Baseline + Geographic Region+Baseline HbA1c Group + Age + Treatment\*Time. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline)=Unstructured.

Time frame:
Baseline, Week 104
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning Score
score on a scaleTirzepatideIntensified Conventional Care (ICC)
Change From Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning Score13.96 ± 0.9519.33 ± 0.961
Statistical analysis
  • Tirzepatide vs Intensified Conventional Care (ICC) · Mixed Models Analysis · p = <.001 · Ls mean difference (net): 4.63 · 95% CI 1.97 to 7.29
SecondaryChange From Baseline in the IWQOL-Lite-CT - Physical Functioning Score
Time frame:
Baseline, Week 208

Results for this outcome have not been posted.

Adverse events

Collected over Baseline up to Week 104. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide2/397 (0.5%)22/397 (5.5%)223/397 (56.2%)
Intensified Conventional Care (ICC)2/395 (0.5%)27/395 (6.8%)165/395 (41.8%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventTirzepatideIntensified Conventional Care (ICC)
OsteoarthritisMusculoskeletal and connective tissue disorders1/3972/395
CholecystitisHepatobiliary disorders2/3970/395
Cholecystitis acuteHepatobiliary disorders2/3971/395
Aortic aneurysmVascular disorders2/3970/395
Intermenstrual bleedingReproductive system and breast disorders0/1811/210
Uterine polypReproductive system and breast disorders0/1811/210
Seminal vesicular cystReproductive system and breast disorders1/2160/185
BradycardiaCardiac disorders0/3971/395
Myocardial infarctionCardiac disorders0/3971/395
Ventricular fibrillationCardiac disorders0/3971/395
Most frequent other events
Most frequent other events
EventTirzepatideIntensified Conventional Care (ICC)
NauseaGastrointestinal disorders90/39769/395
DiarrhoeaGastrointestinal disorders87/39753/395
DyspepsiaGastrointestinal disorders68/39725/395
ConstipationGastrointestinal disorders57/39746/395
VomitingGastrointestinal disorders55/39741/395
EructationGastrointestinal disorders27/3976/395
InfluenzaInfections and infestations18/39723/395
Decreased appetiteMetabolism and nutrition disorders22/39714/395
HeadacheNervous system disorders22/39712/395
NasopharyngitisInfections and infestations10/39721/395

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)TirzepatideIntensified Conventional Care (ICC)Total
Mean53.7 ± 10.853.2 ± 9.753.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)TirzepatideIntensified Conventional Care (ICC)Total
Female181211392
Male217185402
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TirzepatideIntensified Conventional Care (ICC)Total
Hispanic or Latino423779
Not Hispanic or Latino454893
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TirzepatideIntensified Conventional Care (ICC)Total
American Indian or Alaska Native455196
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American232548
White327320647
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)TirzepatideIntensified Conventional Care (ICC)Total
Canada5813
Argentina9284176
Romania354176
United States8785172
Italy7916
Mexico100104204
United Kingdom141024
Israel201535
Slovakia222244
Germany161834
Hemoglobin A1
Hemoglobin A1(Percentage of HbA1c)TirzepatideIntensified Conventional Care (ICC)Total
Mean7.83 ± 0.807.79 ± 0.847.81 ± 0.82
08

Study locations

90 sites
09

References and documents

Publications

  • Del Prato S, Heine RJ, Perez Manghi FC, Hsia SH, Gomez-Valderas E, Zeytinoglu M, Razzoli E, Kiljanski J, Sharma P, Knights A, Thieu VT. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. Ann Intern Med. 2026 Jul;179(7):917-928. doi: 10.7326/ANNALS-25-05602. Epub 2026 May 26. PubMed 42184419 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2025, 38 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 38 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2022
First posted
Jun 27, 2022
StartActual
Aug 1, 2022
Primary completionActual
Oct 21, 2025
CompletionEst.
Nov 2027
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Enrollment
780 (estimated)→794 (actual)
Nov 12, 2026
Interventions
Arm changed Intensified Conventional Care Dose→Intensified Conventional Care (ICC)
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 104
Nov 12, 2026
Documents
Secondary outcomes
18 edited, 12 added, 19 more
What changed in the outcomes
  • EditedChange fromFrom Baseline in HbA1cTime frame: Baseline, Week 208
  • EditedChange fromFrom Baseline in WeightTime frame: Baseline, Week 104
  • EditedChange fromFrom Baseline in WeightTime frame: Baseline, Week 208
  • EditedChange fromFrom Baseline in Waist CircumferenceTime frame: Baseline, Week 104
  • EditedChange fromFrom Baseline in Waist CircumferenceTime frame: Baseline, Week 208
  • EditedChange fromFrom Baseline in Fasting Serum Glucose (FSG)Time frame: Baseline, Week 104
  • EditedChange fromFrom Baseline in FSGFasting Serum GlucoseTime frame: Baseline, Week 208
  • EditedPercent Change fromFrom Baseline in LipidsTotal Serum CholesterolTime frame: Baseline, Week 104
  • EditedPercent Change fromFrom Baseline in LipidsTotal Serum CholesterolTime frame: Baseline, Week 208
  • EditedPercent Change fromFrom Baseline in β-cell Glucose SensitivitySerum TriglyceridesTime frame: Baseline, Week 104
  • EditedPercent Change fromFrom Baseline in β-cell glucose sensitivitySerum TriglyceridesTime frame: Baseline, Week 208
  • EditedChange fromFrom Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)Time frame: Baseline, Week 104
  • EditedChange fromFrom Baseline in Insulin Secretion Rate at a Fixed Glucose ConcentrationTime frame: Baseline, Week 208
  • EditedChange fromFrom Baseline in PostprandialOral Glucose Insulin Sensitivity Indices(OGIS)Time frame: Baseline, Week 104
  • EditedChange fromFrom Baseline in PostprandialOral Glucose Insulin Sensitivity Indices(OGIS)Time frame: Baseline, Week 208
  • EditedChange fromFrom Baseline in Fasting and Post-challenge Glucose [total and incrementalDuring Oral Glucose Tolerance Test (OGTT) (Incremental AUC(₀[0-₂₄₀min180])]Time frame: Baseline through Week 104 → Baseline, Week 104
  • EditedChange fromFrom Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning DomainScoreTime frame: Baseline, Week 104
  • EditedChange fromFrom Baseline in the IWQOL-Lite-CT - Physical Functioning DomainScoreTime frame: Baseline, Week 208
  • AddedPercent Change From Baseline in Serum Low-density Lipoprotein (LDL) CholesterolTime frame: Baseline, Week 104
  • AddedPercent Change From Baseline in Serum Low-density Lipoprotein (LDL) CholesterolTime frame: Baseline, Week 208
  • AddedPercent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) CholesterolTime frame: Baseline, Week 104
  • AddedPercent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) CholesterolTime frame: Baseline, Week 208
  • AddedPercent Change From Baseline in Serum High-density Lipoprotein (HDL) CholesterolTime frame: Baseline, Week 104
  • AddedPercent Change From Baseline in Serum High-density Lipoprotein (HDL) CholesterolTime frame: Baseline, Week 208
  • AddedPercentage of Participants With >=5% Weight Loss From BaselineTime frame: Baseline, Week 104
  • AddedPercentage of Participants With >=5% Weight Loss From BaselineTime frame: Baseline, Week 208
  • AddedPercentage of Participants With >=10% Weight Loss From BaselineTime frame: Baseline, Week 104
  • AddedPercentage of Participants With >=10% Weight Loss From BaselineTime frame: Baseline, Week 208
  • AddedPercentage of Participants With >=15% Weight Loss From BaselineTime frame: Baseline, Week 104
  • AddedPercentage of Participants With >=15% Weight Loss From BaselineTime frame: Baseline, Week 208
  • …and 19 more, on the record history on ClinicalTrials.gov ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Enrollment 780 (estimated)→794 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 104
    Secondary outcomes 18 edited, 12 added, 19 more
    What changed in the outcomes
    • EditedChange fromFrom Baseline in HbA1cTime frame: Baseline, Week 208
    • EditedChange fromFrom Baseline in WeightTime frame: Baseline, Week 104
    • EditedChange fromFrom Baseline in WeightTime frame: Baseline, Week 208
    • EditedChange fromFrom Baseline in Waist CircumferenceTime frame: Baseline, Week 104
    • EditedChange fromFrom Baseline in Waist CircumferenceTime frame: Baseline, Week 208
    • EditedChange fromFrom Baseline in Fasting Serum Glucose (FSG)Time frame: Baseline, Week 104
    • EditedChange fromFrom Baseline in FSGFasting Serum GlucoseTime frame: Baseline, Week 208
    • EditedPercent Change fromFrom Baseline in LipidsTotal Serum CholesterolTime frame: Baseline, Week 104
    • EditedPercent Change fromFrom Baseline in LipidsTotal Serum CholesterolTime frame: Baseline, Week 208
    • EditedPercent Change fromFrom Baseline in β-cell Glucose SensitivitySerum TriglyceridesTime frame: Baseline, Week 104
    • EditedPercent Change fromFrom Baseline in β-cell glucose sensitivitySerum TriglyceridesTime frame: Baseline, Week 208
    • EditedChange fromFrom Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)Time frame: Baseline, Week 104
    • EditedChange fromFrom Baseline in Insulin Secretion Rate at a Fixed Glucose ConcentrationTime frame: Baseline, Week 208
    • EditedChange fromFrom Baseline in PostprandialOral Glucose Insulin Sensitivity Indices(OGIS)Time frame: Baseline, Week 104
    • EditedChange fromFrom Baseline in PostprandialOral Glucose Insulin Sensitivity Indices(OGIS)Time frame: Baseline, Week 208
    • EditedChange fromFrom Baseline in Fasting and Post-challenge Glucose [total and incrementalDuring Oral Glucose Tolerance Test (OGTT) (Incremental AUC(₀[0-₂₄₀min180])]Time frame: Baseline through Week 104 → Baseline, Week 104
    • EditedChange fromFrom Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning DomainScoreTime frame: Baseline, Week 104
    • EditedChange fromFrom Baseline in the IWQOL-Lite-CT - Physical Functioning DomainScoreTime frame: Baseline, Week 208
    • AddedPercent Change From Baseline in Serum Low-density Lipoprotein (LDL) CholesterolTime frame: Baseline, Week 104
    • AddedPercent Change From Baseline in Serum Low-density Lipoprotein (LDL) CholesterolTime frame: Baseline, Week 208
    • AddedPercent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) CholesterolTime frame: Baseline, Week 104
    • AddedPercent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) CholesterolTime frame: Baseline, Week 208
    • AddedPercent Change From Baseline in Serum High-density Lipoprotein (HDL) CholesterolTime frame: Baseline, Week 104
    • AddedPercent Change From Baseline in Serum High-density Lipoprotein (HDL) CholesterolTime frame: Baseline, Week 208
    • AddedPercentage of Participants With >=5% Weight Loss From BaselineTime frame: Baseline, Week 104
    • AddedPercentage of Participants With >=5% Weight Loss From BaselineTime frame: Baseline, Week 208
    • AddedPercentage of Participants With >=10% Weight Loss From BaselineTime frame: Baseline, Week 104
    • AddedPercentage of Participants With >=10% Weight Loss From BaselineTime frame: Baseline, Week 208
    • AddedPercentage of Participants With >=15% Weight Loss From BaselineTime frame: Baseline, Week 104
    • AddedPercentage of Participants With >=15% Weight Loss From BaselineTime frame: Baseline, Week 208
    • …and 19 more, on the record history on ClinicalTrials.gov ↗
    Interventions Arm changed Intensified Conventional Care Dose→Intensified Conventional Care (ICC)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05433584
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Aug 1, 2022
Primary completion
Oct 21, 2025
Completion
Nov 2027 (estimated)
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion